Stefanie Sarantopoulos, MD, PhD

Associate Professor of Medicine
Assistant Professor of Immunology
Member of the Duke Cancer Institute
Campus mail 152 Jones Bldg, Box 3961, Durham, NC 27710
Email address stefanie.sarantopoulos@duke.edu
In Their Words

Education and Training

  • Fellowship, Hematology/ Oncology, Dana Farber Cancer Institute, 2002 - 2005
  • Chief Resident, Internal Medicine, Boston University School of Medicine, 2001 - 2002
  • Resident, Internal Medicine, Boston University School of Medicine, 1999 - 2001
  • Intern, Internal Medicine, Boston University School of Medicine, 1998 - 1999
  • Ph.D., Boston University School of Medicine, 1998
  • M.D., Boston University, 1998

Publications

DeFilipp, Z., M. Purcell, W. A. C. Harris, D. J. Chandra, C. Gleason, J. Wrammert, S. Sarantopoulos, and E. K. Waller. “Monitoring the kinetics of B-cell recovery following rituximab may guide the management of steroid-refractory chronic GvHD..” Bone Marrow Transplant 51, no. 4 (April 2016): 607–9. https://doi.org/10.1038/bmt.2015.304.

PMID
26642338
Full Text

Anand, S., S. Thomas, T. Hyslop, K. Corbet, C. Gasparetto, G. Long, A. Morris, et al. “Transplantation of Ex vivo Expanded Umbilical Cord Blood (Nicord) Results in Decreased Infection Burden and Hospital Length of Stay in the First 100 Days.” In Bone Marrow Transplantation, 51:S52–53. NATURE PUBLISHING GROUP, 2016.

Scholars@Duke

Arai, Sally, Joseph Pidala, Iskra Pusic, Xiaoyu Chai, Samantha Jaglowski, Nandita Khera, Jeanne Palmer, et al. “A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation..” Clin Cancer Res 22, no. 2 (January 15, 2016): 319–27. https://doi.org/10.1158/1078-0432.CCR-15-1443.

PMID
26378033
Full Text

Poe, Jonathan C., Wei Jia, Zhiguo Li, Frances T. Hakim, Steven Z. Pavletic, Jeremy J. Rose, David A. Rizzieri, et al. “Targeting the Human Notch 2-BCR Axis: A Driver of B-Cell Hyper-Responsiveness in Active Chronic Graft-Versus Host Disease (cGVHD).” In Blood, Vol. 126. AMER SOC HEMATOLOGY, 2015.

Scholars@Duke

Friend, Reed, James Xenakis, Jonathan S. Serody, Terrance Comeau, Don A. Gabriel, Stefanie Sarantopoulos, James Coghill, et al. “Reduced Intensity Continuous Infusion Busulfan for Allogeneic Hematopoietic Cell Transplant Patients with Hematologic Disorders Who Are Ineligible or Inappropriate for Treatment with a More Intensive Therapeutic Regimen: LCCC 0306.” In Blood, Vol. 126. AMER SOC HEMATOLOGY, 2015.

Scholars@Duke

Shea, Thomas C., Christine Walko, Yunro Chung, Anastasia Ivanova, Julia Sheets, Kamakshi Rao, Don Gabriel, et al. “Phase I/II Trial of Dose-Escalated Busulfan Delivered by Prolonged Continuous Infusion in Allogeneic Transplant Patients..” Biol Blood Marrow Transplant 21, no. 12 (December 2015): 2129–35. https://doi.org/10.1016/j.bbmt.2015.07.016.

PMID
26210442
Full Text

Flynn, Ryan, Jessica L. Allen, Leo Luznik, Kelli P. MacDonald, Katelyn Paz, Kylie A. Alexander, Ante Vulic, et al. “Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease..” Blood 125, no. 26 (June 25, 2015): 4085–94. https://doi.org/10.1182/blood-2014-08-595470.

PMID
25852057
Full Text

Baird, Kristin, Leora E. Comis, Galen O. Joe, Seth M. Steinberg, Fran T. Hakim, Jeremy J. Rose, Sandra A. Mitchell, et al. “Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease..” Biol Blood Marrow Transplant 21, no. 6 (June 2015): 1083–90. https://doi.org/10.1016/j.bbmt.2015.03.006.

PMID
25771402
Full Text

Pages